Discussion GLP-1RAs have changed the therapeutic paradigm of T2D as they significantly improve glucose control, also contributing to pleiotropic effects, especially at the cardiovascular level (60), in different clinical scenarios and therapeutic approaches
While the generic name may sound technical or unfamiliar, it reflects the drugs structure or pharmacological class, rather than its branding
Their framework helps explain something my patients describe all the time: the medication turns down the internal, homeostatic drive to eat, the "I'm running low on fuel" signal, but external and emotional cues run on partly separate circuitry
Many diverticula are seen in the sigmoid
Do not take more than 4 doses in any 24-hour period
Readers are encouraged to check the MHRA/emc, EMA EPAR database, and NICE website for the most current status